Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT03567720




Registration number
NCT03567720
Ethics application status
Date submitted
13/06/2018
Date registered
26/06/2018
Date last updated
1/06/2023

Titles & IDs
Public title
Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC
Scientific title
A Phase 2 Multi-Cohort, Open-Label Study of Intratumoral Tavokinogene Telseplasmid Plus Electroporation in Combination With Pembrolizumab +/- Chemotherapy in Patients With Inoperable Locally Advanced/Metastatic Triple-Negative Breast Cancer
Secondary ID [1] 0 0
KEYNOTE-890
Secondary ID [2] 0 0
OMS-I141 (KEYNOTE-890)
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Triple Negative Breast Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Breast

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - tavokinogene telseplasmid
Other interventions - Pembrolizumab
Treatment: Devices - Immunopulse
Treatment: Drugs - nab paclitaxel
Treatment: Drugs - gemcitabine plus carboplatin

Experimental: TAVO-EP plus IV pembrolizumab - Intratumoral Tavokinogene Telseplasmid (tavo, pIL 12) plus Electroporation (ImmunoPulse) in Combination with Intravenous Pembrolizumab (Cohort enrollment completed)

Experimental: TAVO-EP plus IV pembrolizumab with chemotherapy - Intratumoral Tavokinogene Telseplasmid (tavo, pIL 12) plus Electroporation (ImmunoPulse) in Combination with Intravenous Pembrolizumab along with treatment of an approved chemotherapy per standard of care (either nab-paclitaxel or gemcitabine plus carboplatin)


Other interventions: tavokinogene telseplasmid
Intratumoral tavokinogene telseplasmid delivered by electroporation every 6 weeks

Other interventions: Pembrolizumab
Intravenous 3 weekly treatments

Treatment: Devices: Immunopulse
Device that administers electroporation

Treatment: Drugs: nab paclitaxel
intravenous on days 1, 8 and 15 of each 28 day cycle

Treatment: Drugs: gemcitabine plus carboplatin
intravenous on days 1 and 8 of every 21 days
Intervention code [1] 0 0
Other interventions
Intervention code [2] 0 0
Treatment: Devices
Intervention code [3] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Cohort 1: Objective Response Rate (ORR)
Timepoint [1] 0 0
Approximately 2 years
Primary outcome [2] 0 0
Cohort 2: Objective Response Rate (ORR)
Timepoint [2] 0 0
Approximately 2 years
Secondary outcome [1] 0 0
Duration of Response (DOR)
Timepoint [1] 0 0
Approximately 2 years
Secondary outcome [2] 0 0
Progression Free Survival (PFS)
Timepoint [2] 0 0
Approximately 2 years
Secondary outcome [3] 0 0
Immune Progression Free Survival (iPFS)
Timepoint [3] 0 0
Approximately 2 years
Secondary outcome [4] 0 0
Immune Objective Response Rate (iORR)
Timepoint [4] 0 0
Approximately 2 years
Secondary outcome [5] 0 0
Disease Control Rate (DCR)
Timepoint [5] 0 0
Approximately 2 years
Secondary outcome [6] 0 0
Overall Survival
Timepoint [6] 0 0
Approximately 2 years

Eligibility
Key inclusion criteria
1. Subjects with histologically confirmed diagnosis of inoperable locally advanced or
metastatic TNBC.

2. The following prior cancer therapy requirements apply to specific cohorts:

1. For Cohort 1 only, subjects must have received at least 1 prior line of systemic
chemotherapy or immunotherapy that includes an approved regimen.

2. For Cohort 2 only, subjects has had no prior systemic therapy in the
advanced/metastatic setting and must not have progression or recurrence of
disease within 6 months after the last dose of systemic neoadjuvant or adjuvant
treatment, if applicable.

3. Subjects must have TNBC defined as estrogen (ER) receptor and progesterone (PR)
receptor staining <10% and human epidermal growth factor receptor 2 (HER2) - negative
defined as immunohistochemistry (IHC) 0 to 1+

4. For Cohort 2, the participant must meet each of the following criteria:

1. Has baseline PD-L1 negative disease (defined as Dako 22C3 assay CPS<10 [or
equivalent, per sponsor agreement]) with results provided prior to start of study
drug dosing: Historic results or new local PD-L1 testing from tissue collected
within 6 months and without intervening therapy prior to Cycle 1 Day 1

2. Can provide a separate core or punch tumor biopsy collected at screening or
archival tissue collected within 6 months (and without intervening therapy) prior
to Cycle 1 Day 1

3. Has at least one lesion suitable for biopsy on Cycle 2 Day 1 (preferably same
lesion from which the screening sample was collected).

5. Subjects must not have disease that, in the opinion of the Investigator, is considered
amenable to potentially curative treatment.

6. Age = 18 years of age of day of signing informed consent.

7. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

8. Life expectancy of at least 6 months.

9. Participant has measurable disease based on RECIST v1.1 and has at least one
identified lesion (target or non-target) that is accessible (up to 1.5 cm from the
skin surface) and in a safe location for intratumoral injection and electroporation.

10. Demonstrate adequate organ function. All screening laboratories should be performed
within 10 days of treatment initiation.

11. Female participant of childbearing potential must have a negative pregnancy test (for
serum or urine pregnancy test, within 72 hours or 24 hours, respectively, prior to
receiving the first study drug administration). If the urine test is positive or
cannot be confirmed as negative, a serum pregnancy test will be required.

12. Female participant of childbearing potential must be willing to use an adequate method
of contraception from the first day of study treatment (or 14 days prior to the
initiation of study treatment for oral contraception) and through at least 120 days
following the last day of study treatment.

13. Male participant is surgically sterile OR agrees to use an adequate method of
contraception when having sex with women of childbearing potential and refrains from
sperm donation during the study treatment period and at least 120 days following the
last day of study treatment.

14. Participant is able and willing to give informed consent and to follow study
instructions.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Subject has a known additional malignancy that is progressing or requires active
treatment. Exceptions include basal cell carcinoma of the skin or squamous cell
carcinoma of the skin that has undergone potentially curative therapy or in situ
cervical cancer.

2. Subject has a clinically active brain metastases or leptomeningeal metastases.
Participant who has a previously treated brain metastases or untreated asymptomatic
brain metastases =5 mm may participate provided that they are radiologically stable
(ie, without evidence of progression based on imaging during study screening),
clinically stable, and without requirement of steroid treatment for at least 14 days
prior to the first dose of study treatment.

3. Subject has had an allogenic tissue/solid organ transplant.

4. Subjects with electronic pacemakers or defibrillators.

5. Subject who have a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2
antibodies).

6. Subject has active hepatitis B (defined as HBsAg reactive) or active hepatitis C
(defined as HCV RNA [qualitative] is detected). Note: Participant with a history of
HBV or HCV controlled by ongoing viral suppression therapy is allowed.

7. Subject has a diagnosis of immunodeficiency or is receiving chronic systemic steroid
therapy (in dosing exceeding 10 mg/day of prednisone or equivalent) or any other form
of immunosuppressive therapy within 7 days prior to the first dose of study drug.

8. Subject has an active autoimmune disease that required systemic treatment in the past
2 years (ie, with use of disease modifying agents, corticosteroids or
immunosuppressive drugs).

9. Subject has received a live-virus or live-attenuated vaccine within 30 days prior to
the first dose of study treatment. Note: Administration of killed vaccines are
allowed.

Seasonal flu vaccines and COVID-19 vaccines that do not contain live virus (including
attenuated vaccines) are permitted.

10. Subject has severe hypersensitivity (=Grade 3) to pembrolizumab or other anti-PD-1
monoclonal antibody therapy and/or any of its excipients.

11. For Cohort 2 only, participant has severe hypersensitivity (=Grade 3) to or expected
intolerance of the protocol-specified chemotherapy options. Participant must be able
to tolerate at least one of the trial approved chemotherapy options.

12. Subject has received transfusion of blood products (including platelets or red blood
cells) or colony stimulating factors (including G-CSF, GM-CSF, or recombinant
erythropoietin) within 2 weeks prior to qualifying screening labs.

13. Subject has a history of (non-infectious) pneumonitis that required steroids or
current pneumonitis.

14. Subject has a history of interstitial lung disease.

15. Subject has an active infection requiring systemic therapy.

16. Subject has a history or current evidence of any condition, therapy, or laboratory
abnormality that might confound the results of the study, interfere with the subject's
participation for the full duration of the study, or is not in the best interest of
the subject to participate, in the opinion of the treating Investigator.

17. Participant has not recovered (ie, =Grade 1 or at baseline) from adverse events (AEs)
due to a previously administered agent.

18. Subject has received any systemic anti-cancer agent or other local anti-cancer
immunotherapy within 14 days prior to the start of study treatment.

19. Subject has a known psychiatric or substance abuse disorder that would interfere with
the participant's ability to cooperate with the requirements of the study.

20. Subject is pregnant or breastfeeding or expecting to conceive or father children
within the projected duration of the study, starting with the screening visit through
120 days after the last dose of study treatment.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
11/10/2018
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/09/2024
Actual
Sample size
Target
65
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC
Recruitment hospital [1] 0 0
Westmead Hospital - Westmead
Recruitment hospital [2] 0 0
Princess Alexandra Hospital - Woolloongabba
Recruitment hospital [3] 0 0
Calvary Central Districts Hospital - Elizabeth Vale
Recruitment hospital [4] 0 0
Box Hill Hospital - Box Hill
Recruitment postcode(s) [1] 0 0
2145 - Westmead
Recruitment postcode(s) [2] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [3] 0 0
5112 - Elizabeth Vale
Recruitment postcode(s) [4] 0 0
3128 - Box Hill
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Ohio
Country [7] 0 0
United States of America
State/province [7] 0 0
Virginia
Country [8] 0 0
United States of America
State/province [8] 0 0
Washington

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
OncoSec Medical Incorporated
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Merck Sharp & Dohme LLC
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
This is a Phase 2, Multi-Cohort, Open-Label, Multi-Center Study. Cohort 1 will be a
single-arm study of intratumoral tavokinogene telseplasmid (TAVO) plus electroporation (EP)
in combination with pembrolizumab therapy. Cohort 2 will be a single-arm study of
intratumoral TAVO-EP plus pembrolizumab along with treatment of an approved chemotherapy per
standard of care (either nab-paclitaxel (Abraxane®) or gemcitabine (Gemzar®) plus carboplatin
(Paraplatin®)) in participants with TNBC and no prior systemic therapy in the advanced or
metastatic setting will be enrolled in this study.
Trial website
https://clinicaltrials.gov/ct2/show/NCT03567720
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Bridget O'Keeffe
Address 0 0
OncoSec Medical Incorporated
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT03567720